Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
lol- the jacbob rees mogg of LSE like I said- NDN. Ashfield is much more than a PR company ffs! MSL's aren't even allowed to promote and must be reactive in the pre-license setting. Reactive. So the questions come from the clinician. Why would questions arise from clinicians unless the data is positive/EUA approved!
Thank you all, having been here for a couple of years, although I don't post too often, I have read everything in some detail and do have faces for you all in my head (however weird that may seem) lol. I agree, deffo not looking to become a pharma comp, but nonetheless, who knows what the T/O price will be. Could be £8,10,20+
apologies Doc, I know we have had a few of these threads before. I anticipate phase 3 results to lead to £5, and then EUA submission and acceptance probably a few weeks after where the sky is the limit. And then the orders...
I know we have had posts like this in the past, but I am really struggling to pick a price to sell/derisk. I am one of the numpties that bought at 39p and then sold on the bell at 100p on manic monday only for it to rise to 220p on the day....
I am so so happy with this RNS. Ashfield would LOVE to partner with big pharma, an AZ or a Roche even if there is a 50% chance of success. It means they form relationships with big pharma companies, if successful then great, if not successful then relationships have been established. However, for little old SNG to partner with them, there has to be a very high chance of success otherwise there isn't a huge benefit for Ashfield.
It is only a matter of time.
you don't just get sent data on the day and then create an RNS- you have the data for several weeks before an announcement where you analyse the results thoroughly. They 1000000% know the topline results. Simple as that.
NDN is the Jacob Rees Mogg of LSE- someone who speaks with utmost confidence, blinding people into belief. The team will 100% know the topline numbers and the biostatisticians will be working on the whole data package alongside the clinical scientists.